Antenatal magnesium sulphate neuroprotection in the preterm infant
Antenatal magnesium sulphate neuroprotection in the preterm infant
复制标题
DOI：
10.1016/j.siny.2007.04.001
复制
发表时间：
2007-08-01
影响因子：
3
通讯作者：
Middleton, Philippa
中科院分区：
文献类型：
--
作者：
Marret, Stephane;Doyle, Lex W.;Middleton, Philippa
极早产儿神经损伤和残疾的发生率很高。随着存活率的提高，这些比率并没有降低。基础科学研究表明，出生前服用硫酸镁可以对早产儿起到神经保护作用。一些（但不是全部）人类观察性研究也表明产前硫酸镁对脑瘫有保护作用。四项产前硫酸镁随机对照试验报告了对存活婴儿的长期神经学影响，但其中只有一项是专门为评估治疗的长期影响而设计的。这些研究发现，总体而言，产前硫酸镁治疗对儿科死亡率或生命最初几年的神经系统结局（包括脑瘫）没有显着影响，但一项研究发现它可以降低 2 岁时运动问题的发生率。产前硫酸镁治疗作为早产儿神经保护剂的作用尚未确定。 (C) 2007 Elsevier Ltd. 保留所有权利。
Very preterm infants have high rates of neurological impairments and disabilities. These rates have not diminished as the survival rates have improved. Basic science research suggests that magnesium sulphate before birth can be neuroprotective for the preterm fetus. Some, but not all, observational studies in humans also suggest a protective effect of antenatal magnesium sulphate on cerebral palsy. Four randomised controlled trials of antenatal magnesium sulphate have reported tong-term neurological effects in surviving infants, but only one of these was designed specifically to evaluate the tong-term effects of treatment. These studies found that, overall, antenatal magnesium sulphate therapy had no significant effect on paediatric mortality or neurological outcomes in the first few years of life, including cerebral palsy, but it was found to lower the rate of motor problems at 2 years of age in one study. The role for antenatal magnesium sulphate therapy as a neuroprotective agent for the preterm fetus is not yet established. (C) 2007 Elsevier Ltd. All rights reserved.